Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
Morgan Stanley just reframed the revenue story for Tempus AI in a way that management's own guidance never fully captured, and the market is now scrambling to catch up with what reimbursement clarity actually means for the bottom line.
Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 spotlighted fresh reimbursement-driven revenue lifts for the AI-powered diagnostics company. Shares have rallied 29.98% over the past week, extending into a 13.83% surge in Thursday’s session to $79.65. For long-term investors, the commentary reframes the near-term revenue trajectory well beyond management’s prior guidance.
| Ticker | Company | Firm | Action | Focus |
|---|---|---|---|---|
| TEM | Tempus AI | Morgan Stanley | Revenue outlook boost | Reimbursement upgrades on xT and xF |
Inside the Analyst’s Revenue Case
The Morgan Stanley discussion centered on how newly clarified reimbursement pricing translates directly into incremental revenue. CEO Eric Lefkofsky estimated that xT pricing adds $80 million to $100 million next year, while xF approval and pricing could add $250 million to $300 million annually. Lefkofsky also signaled that Tempus should over-deliver on its stated 25% multiyear growth target.
Those figures line up with prepared remarks from the Q2 call, where management guided to approximately $400 million of revenue uplift in 2028 across the XT CDx and XF approvals, and pegged the minimal residual disease opportunity from the pending Personalis deal at a $20 billion plus market.
Tempus AI Snapshot
Tempus is a Chicago-based precision medicine platform with two segments: Diagnostics and Data and Applications. Q2 FY2026 revenue reached $382.49 million, up 21.6% year over year, with oncology testing volumes accelerating 31%. The company raised full-year guidance to $1.595 to $1.605 billion, or roughly 25% annual growth, and reaffirmed adjusted EBITDA of about $65 million. Market capitalization sits near $14.0 billion.
Data licensing bookings totaled approximately $200 million in the quarter, with named customers including AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Daiichi Sankyo, Levelset Bio, and Insight Pharmaceuticals. Lefkofsky said “The data business is just on fire.”
Why the Rally Is Landing Now
The setup matters because analyst sentiment was already turning. Forward EPS estimates for fiscal 2027 have swung from -$0.1067 ninety days ago to $0.0040 today, with eight upward revisions in the past 30 days. Wall Street’s consensus revenue estimate for FY2027 sits at $1.97 billion. Shares trade at roughly 9x sales, and the stock remains below its 52-week high of $104.32 despite a 54.24% one-month gain. The consensus analyst target price of $68.18 now trails the market price, suggesting further target revisions may follow.
What It Means for Your Portfolio
Retirement-focused readers should weigh Tempus AI stock as a high-beta growth story: beta of 3.7, ongoing GAAP losses, and heavy stock-based compensation of $54.1 million in Q2. Yet the reimbursement clarity, accelerating data licensing, and pending Personalis MRD platform sharpen a credible path to positive free cash flow by year end. The price target raised commentary from Morgan Stanley reframes the setup, though position sizing should reflect the volatility that comes with it (we studied what the early traits of the biggest tech winners looked like and put them in a free playbook here).
Contact [email protected] for any questions or corrections.
After two decades of patrolling the dark corners of suburbia as a police officer, Rich Duprey hung up his badge and gun to begin writing full time about stocks and investing. For the past 20 years, he’s been cruising the markets looking for companies to lock up as long-term holdings in a portfolio while writing extensively on the broad sectors of consumer goods, technology, and industrials. Because his experience isn’t from the typical financial analyst track, Rich is able to break down complex topics into understandable and useful action points for the average investor. His writings have appeared on The Motley Fool, InvestorPlace, Yahoo! Finance, Money Morning, and, of course, 24/7 Wall St. He has been featured in both U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, and USA Today.
